Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.65 USD

16.65
8,401,707

-0.43 (-2.52%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $16.66 +0.01 (0.06%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TEVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Teva Pharmaceutical Industries Ltd. [TEVA]

Reports for Purchase

Showing records 441 - 458 ( 458 total )

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 441

08/02/2011

Company Report

Pages: 12

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 442

07/07/2011

Company Report

Pages: 11

Short term outlook remains bleak in view of ongoing manufacturing issues

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 25.00

Research Provided by a Third Party

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 443

06/08/2011

Company Report

Pages: 13

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 444

05/13/2011

Company Report

Pages: 11

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 445

04/25/2011

Company Report

Pages: 2

Buy on Pullback from MS Competition

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 446

04/19/2011

Company Report

Pages: 13

Latest moderate setback on Laquinimod adds further to near term concerns.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 447

04/19/2011

Company Report

Pages: 12

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 448

02/17/2011

Company Report

Pages: 11

At 10x CY11E earnings

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 25.00

Research Provided by a Third Party

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 449

02/07/2011

Company Report

Pages: 11

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 450

11/18/2010

Company Report

Pages: 11

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 451

11/12/2010

Company Report

Pages: 11

Generic pipeline still remains the best in generic pharma space

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 25.00

Research Provided by a Third Party

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 452

08/13/2010

Company Report

Pages: 11

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 453

06/28/2010

Company Report

Pages: 16

Spate of acquisitions boost topline & bottomline growth.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 454

05/12/2010

Company Report

Pages: 10

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 455

03/03/2010

Company Report

Pages: 10

Price: 24.95

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 456

02/16/2010

Daily Note

Pages: 2

MORNING NOTE

Provider: M PARTNERS, INC.

Price: 10.00

Research Provided by a Third Party

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 457

02/12/2010

Industry Report

Pages: 5

Opportunities and Perils from the Mobile Data Tsunami

Provider: WEDBUSH SECURITIES INC.

Analyst: SUTHERLAND S

Price: 10.00

Research Provided by a Third Party

Company: Teva Pharmaceutical Industries Ltd.

Industry: Medical - Generic Drugs

Record: 458

01/19/2010

Company Report

Pages: 11

Price: 24.95